Economic Burden of Binge-Eating Disorder Quantified

Share this content:
Economic Burden of Binge-Eating Disorder Quantified
Economic Burden of Binge-Eating Disorder Quantified

MONDAY, Nov. 21, 2016 (HealthDay News) -- Individuals with binge-eating disorder (BED) have significantly greater economic burden compared to those without BED, according to a study published online Nov. 16 in the International Journal of Eating Disorders.

You-Li Ling, Ph.D., from the University of Texas at Austin, and colleagues quantified the economic burden of BED among respondents of the U.S. National Health and Wellness Survey 2013 who were invited to participate in a follow-up internet survey. A total of 1,720 individuals were included in the analysis: 344 with BED and 1,376 without BED.

The researchers found that the levels of activity impairment were higher for BED respondents than non-BED respondents (41.29 versus 23.18 percent; P < 0.001). The 178 employed BED respondents had a greater level of work impairment than the 686 employed non-BED respondents (36.83 versus 14.41 percent; P = 0.009). BED respondents had higher health care resource utilization than matched non-BED respondents, with more surgeries (0.23 versus 0.13; P = 0.021), emergency room visits (0.26 versus 0.15; P = 0.016), and physician visits (6.09 versus 4.56; P = 0.002). Compared with matched non-BED respondents, BED respondents reported higher total direct costs ($20,194 versus $14,465; P = 0.005). Indirect costs were higher among employed BED respondents than those without BED ($19,327 versus $9,032; P < 0.001).

"Individuals with BED reported significantly greater economic burden with respect to work productivity loss, level of health care resource utilization, and costs compared to non-BED respondents," the authors write.

Several authors disclosed financial ties to Shire Development, which funded the study.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Approves Zejula for Certain Female Cancers

FDA Approves Zejula for Certain Female Cancers

PARP inhibitor may help fight tumors affecting the ovaries, fallopian tubes, or peritoneum

USPSTF: Evidence Lacking for Celiac Dz Screen in Asymptomatic

USPSTF: Evidence Lacking for Celiac Dz Screen in ...

Insufficient evidence for weighing benefits, harms of screening for celiac disease in asymptomatic

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Lap, Abdominal Hysterectomy Equal for Early Endometrial CA

Equivalent disease-free survival at 4.5 years for stage I endometrial cancer with TAH, TLH

is free, fast, and customized just for you!

Already a member?

Sign In Now »